Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Abbvie Inc
N.ABBV
Primary Symbol:
ABBV
Healthcare
Biotechnology
AbbVie Inc. is a diversified research-based biopharmaceutical company engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers a comprehensive product portfolio across Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and Other Specialties. Immunology includes Rheumatology, Dermatology, and Gastroenterology. Oncology...
includes Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Diffuse large B-cell lymphoma, and others. Neuroscience includes Parkinson's disease, Migraine, Movement Disorders, Psychiatric Disorders, and Alzheimer’s disease. Eye Care includes Chronic Dry Eye Disease, Glaucoma, Age-Related Retinal Diseases, and Refractive Disorders. Aesthetics includes Botox Cosmetic, The Juvederm Collection of Fillers, and others. It offers NX-13 for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). It also offers CEL383 for the treatment of inflammatory bowel disease.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NYSE:ABBV)
New Post
View:
Posts & Comments
Threaded Posts
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Nov 25, 2024 8:01am
New Press Release - AbbVie to Present at Citi's 2024 Global Healthcare Conference
NORTH CHICAGO, Ill., Nov. 25, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024. Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial...
read article.
(6)
•••
BlazeFinance98
X
View Profile
View Bullboard History
Post by
BlazeFinance98
on Nov 24, 2024 12:57pm
🚀 ABBV Up 14% – Keep an Eye on MYNZ!
ABBV’s strong earnings and analyst upgrades make it look good, with targets reaching $225. Debt’s a bit high, but institutional confidence is solid. Plus, that dividend’s nice.Also, MYNZ’s been
...more
QMET has 11 claims and 633 hectares Property in Ville-Marie, Quebec Hydrogen Camp
posted Nov 25, 2024 9:00am by
Q Precious & Battery Metals Corp.
-
|
The Company is pleased to discover that their Lorrain claims are now within the new and exciting exploration for hydrogen in the Ville-Marie, Lorrainville and Béarn region of Quebec. The region has undergone a claim staking rush following the ...read more
(1)
•••
TradeSphere83
X
View Profile
View Bullboard History
Post by
TradeSphere83
on Nov 22, 2024 1:31pm
AbbVie Gains Momentum Amid Analyst Upgrade
AbbVie surged nearly 4% today following an analyst upgrade, signaling strong momentum. Despite a recent hurdle with its schizophrenia drug, emraclidine, its strategic Cerevel Therapeutics acquisition
...more
(2)
•••
MarketPilot42
X
View Profile
View Bullboard History
Post by
MarketPilot42
on Nov 22, 2024 9:18am
Dividend Growth Play
ABBV's div hike to $1.64 is no joke! That’s a 5.8% boost—perfect for income stacking while we wait for the next Skyrizi breakout. Who's holding ABBV for the long haul? Also keeping an eye on
...more
•••
Jonathon Brown
X
View Profile
View Bullboard History
Post by
Jonathon Brown
on Nov 21, 2024 6:55am
Buzz on the Bullboards: Bombardier, world woes, a smart fridge, and top shelf weed
A highlight of the week was Bombardier (TSX:BBD), which reported impressive growth in its Q3 2024 results.
read article.
(233)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Oct 30, 2024 5:00pm
Canadian Companies Moving the Markets, Evening edition
W
BREAKING NEWS: $ABBV Canadian Companies Moving the Markets, Evening edition Wed, Oct 30, 2024 as of 4:00 pm ETA look at the top 10 most actives in Canada Talon Metals Corp. (TLO) rose 0.0% to $0.085
...more
(233)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Oct 30, 2024 4:45pm
3 Dividend Growth Stocks to Buy and Never Sell
News; $ABBV 3 Dividend Growth Stocks to Buy and Never Sell2024-10-30 07:00:00 ET The power of dividend growth investing lies in one simple truth: Companies that consistently raise their dividends have
...more
(233)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jul 17, 2024 5:02pm
3 Absurdly Cheap Stocks to Buy and Hold for Years
News; $ABBV 3 Absurdly Cheap Stocks to Buy and Hold for Years2024-07-17 08:25:00 ET Stocks that are trading at low- and discounted-earnings multiples can sometimes be value traps. But other times, it&
...more
(11)
•••
Wrywisdom
X
View Profile
View Bullboard History
Post by
Wrywisdom
on Aug 10, 2022 3:21pm
Incredible Value. ENTG at about 25% of One Years Revenue
.with revenues now demonstrating an upward Trajectory amd likely attaining profitability within a couple of quarters. May reportage for example indicates record first quarter 2022 results:
...more
(2)
•••
zeropointenergy
X
View Profile
View Bullboard History
Post by
zeropointenergy
on Oct 06, 2021 7:20am
ONE DRUG PILL WIPES OUT COVID 19!
India's Ivermectin Blackout - Part V: The Secret Revealed ... Sep 27, 2021 · By September 12, 2021, Livemint reported that 34 districts were declared COVID-free
...more
(33)
•••
plomar2011
X
View Profile
View Bullboard History
Post by
plomar2011
on Sep 01, 2021 1:58pm
what was the big drop ?? saw no news
what was the big drop ?? saw no news
(1)
•••
edwardebreen15
X
View Profile
View Bullboard History
Post by
edwardebreen15
on Aug 02, 2021 8:42am
Multiple Sclerosis Therapies Market Industry Growth 2026
According to IMARC Group’s latest report, titled “Multiple Sclerosis Therapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026”, The global multiple sclerosis
...more
(3)
•••
Mil_Man54
X
View Profile
View Bullboard History
Post by
Mil_Man54
on Dec 26, 2020 8:13am
Bonvoyage12....Lying Pumper
Ignore this clown as he posts lies trying to mislead investors about the actual state of the company...he also posts this same BS on multiple boards
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
One Property, One Focus on Advancing this Gold Project in Ontario
Options Trading for Retiring: Key Strategies in Balancing Retirement Income